{"contentid": 488606, "importid": NaN, "name": "Cabometyx continues to show promise for Ipsen and Exelixis", "introduction": "Parisian biotech has exercised an option to collaborate with Exelixis on further development of Cabometyx (cabozantinib) in thyroid cancer.", "content": "<p><span style=\"font-weight: 400;\">Parisian biotech Ipsen (Euronext: IPN) has exercised an option to collaborate with Exelixis (Nasdaq: EXEL) on further development of Cabometyx (cabozantinib) in thyroid cancer.</span></p>\n<p><span style=\"font-weight: 400;\">Cabozantinib is a targeted cancer drug that binds to multiple tyrosine kinase receptors, with approvals in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).</span></p>\n<p><span style=\"font-weight: 400;\">Ipsen has been working with the USA-based company </span><a href=\"https://www.thepharmaletter.com/article/ipsen-gains-certain-rights-to-exelixis-cabozantinib-in-multimillion-dollar-deal\"><span style=\"font-weight: 400;\">since 2016</span></a><span style=\"font-weight: 400;\">, with the firms sharing development and commercialization rights in different territories.</span></p>\n<p><span style=\"font-weight: 400;\">In 2020, net product revenues generated by the cabozantinib franchise in the USA were $742 million, while Ipsen generated about $350 million in sales outside of the USA and Japan.</span></p>\n<h2><strong>Thyroid cancer&nbsp;</strong></h2>\n<p><span style=\"font-weight: 400;\">With Ipsen opting in to continued development in thyroid cancer, the companies will collaborate on the Phase III COSMIC-311 trial, which tests Cabometyx against placebo for certain people with radioiodine-refractory differentiated thyroid cancer (DTC).</span></p>\n<p><span style=\"font-weight: 400;\">The firms are looking to broaden the label to include later-line treatment in this indication, after treatment with VEGFR-targeted therapies.</span></p>\n<p><span style=\"font-weight: 400;\">Ipsen&rsquo;s R&amp;D head, Howard Mayer, noted that a planned interim analysis of the trial &ldquo;has shown promising and clinically meaningful results,&rdquo; for a patient population which &ldquo;currently has limited treatment options.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">The analysis showed that COSMIC-311 met its co-primary endpoint of progression-free survival (PFS), with detailed results due to be presented at the annual meeting of ASCO, from 4 to 8 June.</span></p>\n<p><span style=\"font-weight: 400;\">Ipsen has an exclusive collaboration agreement with Exelixis for the commercialization of Cabometyx outside of the USA and Japan. Following the decision to opt-in to the COSMIC-311 trial, Ipsen gains access to the results to support potential future regulatory submissions in its territories.</span></p>\n<p><span style=\"font-weight: 400;\">The US regulator has granted Breakthrough Therapy designation for the use of Cabometyx in this indication.</span></p>", "date": "2021-05-12 12:13:00", "meta_title": NaN, "meta_keywords": "Ipsen, Cabometyx, cancer, thyroid, Exelixis, cabozantinib, development, collaborate, treatment, COSMIC-, trial, results, Nasdaq, EXEL, option, exercised", "meta_description": "Parisian biotech has exercised an option to collaborate with Exelixis (Nasdaq: EXEL) on further development of Cabometyx (cabozantinib) in thyroid cancer.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-12 12:12:37", "updated": "2021-05-12 12:44:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/cabometyx-continues-to-show-promise-for-ipsen-and-exelixis", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "ipsen-logo-big.jpg", "image2id": "ipsen-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Deals, Drug Trial, Licensing, Management, Research", "geography_tag": "France, USA", "company_tag": "Exelixis, Ipsen", "drug_tag": "Cabometyx", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-12 12:13:00"}